Evidence map›Paper›PMID 41235439›Full record

ReviewAsia-Pacific journal of clinical oncology2026

Quercetin as a Therapeutic Agent for Oral Cancer: Current Evidence and Future Directions.

Hua Sun, Huihui Wang, Shujiang Guo

Abstract readReview
In one paragraph

Review in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hua SunOral Cavity Teaching and Research Section, Medical School, Hebi Polytechnic College, Hebi, China.
Huihui WangDepartment of Neurology, The Second People's Hospital of Xinxiang, Xinxiang, China.
Shujiang GuoDepartment of Stomatology, General Hospital of Hebi Coal Industry (Group) Co, Hebi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral cancer, specifically oral squamous cell carcinoma, is rapidly progressive, with a high recurrence rate and grave prognosis. Treatment modalities like surgery, chemotherapy, and radiotherapy are customarily associated with noxious side effects as well as drug resistance. The food constituent flavonoid quercetin has been identified as anticancer through several mechanisms, including apoptosis induction, suppression of metastasis, cell cycle arrest, and chemosensitization. Its clinical application is, however, restricted by poor systemic absorption. Novel nano-formulations such as liposomes, polymeric nanoparticles, etc., have emerged for improving the stability, bioavailability, and therapeutic action of quercetin. Artificial intelligence has also been reported to be of potential use in predicting patient response to quercetin, recognizing new molecular targets, and customizing treatment regimens. Future research should be conducted with clinical trials to establish the effectiveness of quercetin as an adjuvant treatment and fine-tune targeted delivery systems for it. There is a therapeutic promise for quercetin across multiple types of oral cancer due to its multi-targeting potential. Quercetin, in combination with traditional and immunotherapeutic strategies, represents a promising new strategy with the potential to overcome treatment barriers and reduce toxicity in oral cancer management.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellMouth NeoplasmsQuercetinHumansAntineoplastic AgentsQuercetinapoptosisdrug resistancenano‐formulationsoral squamous cell carcinomaquercetin

Identifiers

PMID41235439
PMCPMC13568874

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.